SPECTRA: A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (clinicaltrials.gov) - Aug 29, 2022 - P2/3 | N=31454 | Active, not recruiting | Sponsor: Clover Biopharmaceuticals AUS Pty Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2022 ➔ Apr 2023
Enrollment closed • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
|